AstraZeneca Breast Cancer Pill Fails in Key Study While FDA Expands Bayer Approval
AstraZeneca's breast cancer drug failed a late-stage trial, while the FDA expanded approval for a Bayer lung cancer treatment and cleared an AstraZeneca COPD medication.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The story so far
2 publishers have covered this in 8 articles since 8 Sept 2026. STAT published first, on 8 September at 11:45 UTC; Bloomberg.com followed 81h 09m later. The most recent article, from STAT, appeared on 12 September at 07:09 UTC.
Outlets reporting it: Bloomberg.com (major outlet), STAT.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
- STATSTAT+: AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies
- STATSTAT+: FDA approves AstraZeneca breast cancer drug
- STATSTAT+: Pharmalittle: We’re reading about an AstraZeneca COPD win, the FDA filling key jobs, and more
- STATSTAT+: Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon
- STATSTAT+: FDA expands Bayer lung cancer drug approval
- Bloomberg.comAstraZeneca Says Breast Cancer Pill Fails in Key Study
- STATSTAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss
- STATSTAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial
Sources
Every article we clustered into this story. Headlines link to the publisher.
- AstraZeneca Says Breast Cancer Pill Fails in Key Study Bloomberg.com ·
- STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial STAT
- STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss STAT
- STAT+: FDA expands Bayer lung cancer drug approval STAT
- STAT+: Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon STAT
- STAT+: Pharmalittle: We’re reading about an AstraZeneca COPD win, the FDA filling key jobs, and more STAT
- STAT+: FDA approves AstraZeneca breast cancer drug STAT
- STAT+: AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies STAT
In this story
- AstraZeneca
- FDA